India · Delayed Price · Currency is INR Venus Remedies Statistics
Total Valuation
Venus Remedies has a market cap or net worth of INR 19.54 billion. The enterprise value is 18.76 billion.
| Market Cap | 19.54B |
| Enterprise Value | 18.76B |
Important Dates
The last earnings date was Monday, October 26, 2026.
| Earnings Date | Oct 26, 2026 |
| Ex-Dividend Date | Aug 7, 2026 |
Share Statistics
Venus Remedies has 13.37 million shares outstanding. The number of shares has increased by 0.08% in one year.
| Current Share Class | 13.37M |
| Shares Outstanding | 13.37M |
| Shares Change (YoY) | +0.08% |
| Shares Change (QoQ) | -0.03% |
| Owned by Insiders (%) | 27.40% |
| Owned by Institutions (%) | 1.48% |
| Float | 7.01M |
Valuation Ratios
The trailing PE ratio is 16.06.
| PE Ratio | 16.06 |
| Forward PE | n/a |
| PS Ratio | 2.33 |
| PB Ratio | 2.77 |
| P/TBV Ratio | 3.16 |
| P/FCF Ratio | 38.85 |
| P/OCF Ratio | 19.36 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 10.91, with an EV/FCF ratio of 37.29.
| EV / Earnings | 15.42 |
| EV / Sales | 2.24 |
| EV / EBITDA | 10.91 |
| EV / EBIT | 12.48 |
| EV / FCF | 37.29 |
Financial Position
The company has a current ratio of 3.31, with a Debt / Equity ratio of 0.02.
| Current Ratio | 3.31 |
| Quick Ratio | 1.70 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | 0.07 |
| Debt / FCF | 0.23 |
| Interest Coverage | 9,001.74 |
Financial Efficiency
Return on equity (ROE) is 18.74% and return on invested capital (ROIC) is 19.24%.
| Return on Equity (ROE) | 18.74% |
| Return on Assets (ROA) | 11.69% |
| Return on Invested Capital (ROIC) | 19.24% |
| Return on Capital Employed (ROCE) | 20.59% |
| Weighted Average Cost of Capital (WACC) | 6.71% |
| Revenue Per Employee | 5.69M |
| Profits Per Employee | 826,624 |
| Employee Count | 1,472 |
| Asset Turnover | 1.04 |
| Inventory Turnover | 3.34 |
Taxes
In the past 12 months, Venus Remedies has paid 368.94 million in taxes.
| Income Tax | 368.94M |
| Effective Tax Rate | 23.27% |
Stock Price Statistics
The stock price has increased by +229.78% in the last 52 weeks. The beta is 0.45, so Venus Remedies's price volatility has been lower than the market average.
| Beta (5Y) | 0.45 |
| 52-Week Price Change | +229.78% |
| 50-Day Moving Average | 1,574.62 |
| 200-Day Moving Average | 1,301.42 |
| Relative Strength Index (RSI) | 48.50 |
| Average Volume (20 Days) | 4,963 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Venus Remedies had revenue of INR 8.37 billion and earned 1.22 billion in profits. Earnings per share was 91.03.
| Revenue | 8.37B |
| Gross Profit | 4.39B |
| Operating Income | 1.50B |
| Pretax Income | 1.59B |
| Net Income | 1.22B |
| EBITDA | 1.71B |
| EBIT | 1.50B |
| Earnings Per Share (EPS) | 91.03 |
Balance Sheet
The company has 901.50 million in cash and 117.40 million in debt, with a net cash position of 784.10 million or 58.66 per share.
| Cash & Cash Equivalents | 901.50M |
| Total Debt | 117.40M |
| Net Cash | 784.10M |
| Net Cash Per Share | 58.66 |
| Equity (Book Value) | 7.05B |
| Book Value Per Share | 527.08 |
| Working Capital | 2.53B |
Cash Flow
In the last 12 months, operating cash flow was 1.01 billion and capital expenditures -506.26 million, giving a free cash flow of 502.96 million.
| Operating Cash Flow | 1.01B |
| Capital Expenditures | -506.26M |
| Depreciation & Amortization | 204.19M |
| Net Borrowing | -26.30M |
| Free Cash Flow | 502.96M |
| FCF Per Share | 37.63 |
Margins
Gross margin is 52.42%, with operating and profit margins of 17.95% and 14.53%.
| Gross Margin | 52.42% |
| Operating Margin | 17.95% |
| Pretax Margin | 18.94% |
| Profit Margin | 14.53% |
| EBITDA Margin | 20.39% |
| EBIT Margin | 17.95% |
| FCF Margin | 6.01% |
Dividends & Yields
This stock pays an annual dividend of 10.00, which amounts to a dividend yield of 0.68%.
| Dividend Per Share | 10.00 |
| Dividend Yield | 0.68% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 10.98% |
| FCF Payout Ratio | 26.58% |
| Buyback Yield | -0.08% |
| Shareholder Yield | 0.60% |
| Earnings Yield | 6.23% |
| FCF Yield | 2.57% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 5 |